Rheumatoid Arthritis

Data from 2 studies presented at ACR 2024 demonstrate the potential of AI to improve access to quality rheumatological assessments.

Over one-third of participants had had inadequate responses or intolerance to at least 3 prior b/tsDMARDs.

However, fewer patients experienced flares in the tofacitinib group than in the placebo group, among other positive findings.

Findings from the first and only controlled study for macrophage activation syndrome were presented at the ACR Convergence.

People who used GC for over 2 years and 3 years had elevated risks of CVD and infection-related mortality, respectively, that never returned to pre-GC use levels.

While an effective and promising strategy for chronic pain relief, more research on long-term cannabis usage is needed.

Highest responders on DAS28 also had significantly greater decreases in 12-hydroxyeicosatetraenoic than low responders.

Veterans residing in rural areas were only 10% more likely to initiate biologic therapies than those residing in rural areas.

A new cohort study including over 6 million participants has found an increased likelihood of Behçet disease, alocpecia, bulbous pemphigoid and other disorders post-COVID infection.

Week 156 efficacy and safety data from the FINCH 4 study are consistent with that seen in FINCH 1, 2, and 3.

Investigators analyzed antibody response after 2 SARS-CoV-2 vaccinations.

The all-optical PAT scanner reduces acquisition time from minutes to seconds and can visualize microvasculature changes to depths approaching 15 mm.

More research is needed to investigate changing trends at presentation and help to inform current treatment strategies.

The data also support the validity of further research into targeting CD-40 signaling in patients with RA not responding to treatment.

In other populations, JAKis demonstrated at least a similar pain benefit to b/tsDMARDs from baseline.

Hs-cTnT was found to be associated with a higher risk of MACE and all-cause mortality in a 10-year cohort study.

Wells discussed the PrismRA blood test, which may benefit planning treatment regimens for patients with rheumatic disease.

Although only 9 patients with FM and nasal septum deviation were included in the study, none met the criteria for fibromyalgia after surgery.

Wells discussed the importance and recommended frequency for several factors, including lipid panels, chest X-rays, pregnancy tests, and flu vaccines.

Patients with high RF concentration treated with CZP were more likely to achieve DAS28-CRP low disease activity at week 104 than those treated with adalimumab.

The MTX + HCQ group had a higher, but not statistically significant, incidence rate of TEAEs than the monotherapy group.

Panelists discuss how head-to-head clinical trial data shape their treatment decisions, the significance of consistent remission rates across different patient populations, and the frequency with which remission data influence their choices to switch therapies.

Panelists discuss advanced treatment options for rheumatoid arthritis, focusing on the SELECT-COMPARE trial's head-to-head data of upadacitinib versus adalimumab, the use of upadacitinib in active RA refractory to biologics (SELECT-BEYOND trial), and the remission rates of upadacitinib compared to abatacept (SELECT-CHOICE trial).

Investigators noted that a formal independent validation cohort needs to be developed in order to realize the full potential of the human model.

Experts discuss American College of Rheumatology guidelines on transitioning patients from TNF inhibitors to non-TNF targeted therapies like Janus kinase inhibitors, as well as factors influencing treatment switching decisions in clinical practice.

Experts discuss strategies for achieving low disease activity or remission in patients, including steps taken in clinical practice and methods for managing patient expectations regarding treatment outcomes.

Lengths of stay, total cost, and hospital mortality rates were similar between patients with and without rheumatoid arthritis.

Investigators also found that bDMARDs were used more often by patients with early-onset rheumatoid arthritis than by patients with late-onset.

A panel of medical experts explore how to evaluate and adjust rheumatoid arthritis treatment by adhering to ACR guidelines for conventional synthetic DMARDs and advanced therapies, focusing on optimizing patient care and treatment outcomes.